Clinical Trials Directory

Trials / Recruiting

RecruitingNCT02445885

Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Thomas Engstrom · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Although recommended therapy for patients with ST-segment elevation myocardial infarction is primary PCI, it remains unestablished whether patients with a symptom duration of more 12 hours benefit from acute revascularisation. This study aims to investigate whether acute intervention is superior to subacute intervention in these patients.

Detailed description

The recommended therapy for patients with ST-segment elevation myocardial infarction (STEMI) is to restore normal coronary blood flow with timely reperfusion by percutaneous coronary intervention (PCI), and thereby minimize the extent of cell death and preserving cardiac function. The duration of ischemia and timely PCI are major determinants for the size of the myocardial infarction and prognosis. Thus, acute PCI should be performed within 12 hours after symptom onset. The effect of PCI and timing of PCI are, however, much more uncertain for late presenters who contact the health service \> 12 hours from symptom. Thus, it is still unknown whether late presenters should be treated with acute PCI or medical treatment with delayed PCI (24-72 h after first medical contact). The study investigates the effect on final salvage index evaluated by magnetic resonance imaging of acute PCI of late presenters. The overall objective of the study is to investigate whether late presenters may benefit from acute PCI, and thus whether to extend the currently recommended time limit of 12 hours for acute PCI in patients with STEMI.

Conditions

Interventions

TypeNameDescription
PROCEDUREPCIGuideline directed Percutaneous Coronary Intervention

Timeline

Start date
2015-05-01
Primary completion
2025-08-30
Completion
2039-03-01
First posted
2015-05-15
Last updated
2026-04-01

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT02445885. Inclusion in this directory is not an endorsement.